Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS

(ALXN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Alexion Pharmaceuticals : Pharma Shares Fall After EU Patent Decision

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/05/2019 | 05:41pm EDT

By Stephen Nakrosis

Shares of Alexion Pharmaceuticals, Inc. (ALXN) are falling in Thursday's after-hours market after it said the European Patent Office decided against granting certain of its patent applications related to Soliris, a treatment for a rare disorder of the nervous system.

At 5:11 p.m. EDT, the company's shares had fallen 3.47% to trade at $96.80. They finished the day's regular trading session with a 2.82% gain, closing at $100.28.

After the bell Thursday, the company said the European Patent Office determined not to grant patent applications "which relate to the pharmaceutical compositions of Soliris (eculizumab) and composition of matter of Soliris."

Alexion said it will evaluate its option to appeal the decision.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALEXION PHARMACEUTICALS
09/10Bridgebio Grants Japanese Rights to Eidos' ag10 to Alexion
AQ
09/09ALEXION : and BridgeBio Announce Japanese License Agreement for Eidos' Transthyr..
BU
09/05ALEXION PHARMACEUTICALS : Pharma Shares Fall After EU Patent Decision
DJ
09/04ALEXION PHARMACEUTICALS : to Present at the 17th Annual Morgan Stanley Global He..
BU
09/03Stocks to Watch: Alphabet, H&R Block, Conn's, and More
DJ
09/03Stocks to Watch: Alphabet, H&R Block, and Alexion Pharmaceuticals
DJ
09/01ALEXION PHARMACEUTICALS : Mike Page, Alexion Pharmaceuticals Invites You to SMi'..
AQ
08/30Alexion Down Over 11%, On Pace for Largest Percent Decrease Since December 20..
DJ
08/28ALEXION PHARMACEUTICALS : European Commission Approves SOLIRIS for the Treatment..
AQ
08/28ALEXION PHARMACEUTICALS : Announces Upcoming Data Presentations at 35th Congress..
BU
More news
Financials (USD)
Sales 2019 4 839 M
EBIT 2019 2 717 M
Net income 2019 1 907 M
Finance 2019 535 M
Yield 2019 -
P/E ratio 2019 12,7x
P/E ratio 2020 11,9x
EV / Sales2019 4,87x
EV / Sales2020 3,94x
Capitalization 24 082 M
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 155,48  $
Last Close Price 107,40  $
Spread / Highest target 71,3%
Spread / Average Target 44,8%
Spread / Lowest Target 12,7%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP, Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS11.20%24 082
CSL LIMITED25.08%72 022
BIOGEN INC.-21.36%43 646
GRIFOLS18.34%18 046
SAMSUNG BIOLOGICS CO LTD--.--%16 471
BIOMARIN PHARMACEUTICAL INC.-14.68%13 038